SightGlass Vision to Present New Myopia Control Research at 2026 Netherlands Contact Lens Congress
Key Takeaways
Two new studies show that SightGlass Vision’s DOT spectacle lenses significantly slowed myopia progression in children across diverse populations
Analysis of clinical trial data found no significant increase in refractive astigmatism among children wearing DOT lenses
The findings add to growing clinical evidence supporting contrast management as a myopia control strategy
SightGlass Vision will present findings from two scientific studies on March 9 at the 2026 Netherlands Contact Lens Congress (NCC), highlighting new evidence supporting the effectiveness and safety profile of its DOT spectacle lenses for slowing myopia progression in children.
The studies focus on the role of contrast management in myopia control, with one examining lens efficacy across diverse populations and the other assessing whether the technology influences refractive astigmatism. The presentations aim to further strengthen confidence among eye care professionals prescribing the lenses.
“Our contributions to this year’s NCC program add to the substantial body of evidence surrounding our innovative DOT spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision. “More than 1.5 million children have already worn these lenses worldwide, and we are committed to helping eye care professionals understand their immense potential through rigorous clinical science and experience.”
One study, “Efficacy of Contrast Management Spectacle Lenses in North American and Chinese Children” (Carta F, et al), analyzed 12-month data from two long-term, multicenter randomized controlled clinical trials. Despite notable differences in participant ethnicity—75% Caucasian and 20% Black in the North American cohort and 100% Chinese in the China cohort—researchers observed significantly slower progression of both axial length (AL) and cycloplegic spherical equivalent refraction (cSER) in children wearing DOT lenses compared with those in control groups. The research was conducted in collaboration with Indiana University.
The second study, “Relationship Between Contrast Management Spectacle Lenses for Myopia Control and Refractive Astigmatism” (Webley D, et al), investigated whether spectacle lenses designed for myopia control could influence the development of astigmatism. Researchers evaluated right-eye refractive data from two long-term multicenter clinical trials in North America and China, assessing astigmatism greater than 0.25 diopters at baseline and after 12 months. The results showed no significant difference in astigmatism changes between the test and control groups, suggesting practitioners can prescribe DOT lenses without increased concern about inducing this unwanted refractive effect. The study was conducted in partnership with Aston University.
The Netherlands Contact Lens Congress will take place March 8-9 at the NH Conference Centre Koningshof in Veldhoven, Netherlands. The annual meeting brings together clinicians, researchers, educators, and industry developers from across the eye care and ocular science community.
DOT lenses are designed to reduce retinal contrast signaling by incorporating microscopic light-scattering elements. The technology is intended to mimic more natural visual contrast conditions, counteracting environmental factors such as increased indoor time and prolonged near work—activities that some research suggests may contribute to accelerated myopia progression in children.
The lenses have been commercially introduced in several markets, including Canada, China, Israel, Spain, and the United Kingdom.
Originally published online on Eyewire+.